Treatment of Mild Colitis

Introduction to Treatment

The standard first-line treatment for patients with mild colitis is mesalamine (5-ASA) at a standard dose of 2-3 grams/day, which effectively induces and maintains remission, as recommended by the American Gastroenterological Association 1, 2

For patients with extensive mild-moderate ulcerative colitis, the American Gastroenterological Association recommends using standard dose mesalamine (2-3 grams/day) or diazo-bonded 5-ASA as initial therapy 2
The American Gastroenterological Association suggests considering once-daily dosing rather than multiple times per day for better adherence in patients with extensive mild-moderate ulcerative colitis 2
For patients with suboptimal response to standard dose mesalamine, the American Gastroenterological Association recommends escalating to high-dose mesalamine (>3 grams/day) with rectal mesalamine 2
For patients with proctosigmoiditis or proctitis, the American Gastroenterological Association recommends using mesalamine enemas or suppositories rather than oral therapy as first-line treatment 2, 3

If standard-dose mesalamine fails to control symptoms, the American Gastroenterological Association recommends increasing to high-dose mesalamine (>3 grams/day) with rectal mesalamine 2
For patients not responding to optimized 5-ASA therapy, the American Gastroenterological Association suggests considering oral prednisone or budesonide MMX 2, 6

Sulfasalazine (2-4g/day) may be considered for patients with prominent arthritic symptoms or those already in remission on this medication, though it has higher rates of intolerance, according to the American Gastroenterological Association 2
Patients with mild-moderate disease but higher risk features may benefit from more aggressive initial therapy, as recommended by the American Gastroenterological Association 7
The American Gastroenterological Association advises avoiding repeated courses of corticosteroids even in mild-moderate disease, and considering escalation of therapy if frequent steroid courses are needed 1

Lifelong maintenance therapy is generally recommended for all patients, especially those with left-sided or extensive disease, according to the European Crohn’s and Colitis Organisation 8
Patients with distal disease who relapse more than once a year should also remain on maintenance therapy, as recommended by the European Crohn’s and Colitis Organisation 8

Regular assessment of response to therapy is essential to determine need for treatment escalation, as recommended by the American Gastroenterological Association 1, 7
Patients with inadequate response to optimized 5-ASA therapy require prompt escalation to prevent disease progression, according to the American Gastroenterological Association 2